Industry

BEIJING–(BUSINESS WIRE)–InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the company has received Investigational New Drug (IND) approval of clinical trial from the NMPA (National Medical Products Administration) for its novel targeted protein degrader ICP-490 for the treatment of multiple myeloma (MM) and … [Read more…]

– Provides additional opportunity for Exelixis to further expand its biotherapeutics development pipeline by combining its tumor-specific targeting approaches with Ryvu’s STING agonist technology, which has best-in-class potential – ALAMEDA, Calif. & KRAKOW, Poland–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) and Ryvu Therapeutics S.A. (“Ryvu”) (Warsaw Stock Exchange: RVU) today announced that the companies have entered into … [Read more…]

A sub-analysis of the Phase 3 LIVE-AIR study of lenzilumab showed a strong correlation between C-reactive protein (CRP) and outcomes with lenzilumab treatment with the greatest clinical benefit experienced by patients with baseline CRP<150 mg/L In these patients, likelihood of survival without mechanical ventilation (SWOV) was achieved in 90% of LIVE-AIR patients treated with lenzilumab … [Read more…]

iHealthScreen is the first company that developed the late AMD prediction model and was awarded a patent by USPTO NEW YORK–(BUSINESS WIRE)–#AI—iPredictTM late AMD prediction model provides a fully automated prediction score for age-related macular degeneration (AMD), and identifies the individuals who are at risk of developing late AMD in 1 year, 2-year or 5-year. … [Read more…]

AHF Press Teleconference: Thurs., July 7 @ 11:00 am PT With case numbers increasing rapidly in L.A. and elsewhere and extremely limited vaccine doses available nationwide, AHF will call on the Los Angeles County Department of Public Health to ramp up public education on the virus and its prevention, as well as share surveillance data … [Read more…]

CAN106 Phase 1 results showed rapid and potent C5 inhibition, complete and sustained blockade of complement activity Data presented at European Hematology Association 2022 Congress and 14th International Conference on Complement Therapeutics CAN106 in Phase 1b/2 study of paroxysmal nocturnal hemoglobinuria in China Shows potential for treating other complement-mediated diseases BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)–CANbridge … [Read more…]

EMERYVILLE, Calif.–(BUSINESS WIRE)–SLINGSHOT BIOSCIENCES, INC., the developers of synthetic cells, today announced they have extended their distribution channel through a new agreement with Chameleon Science. Chameleon Science is an innovative new company specializing in the development and distribution of emerging technologies in Life Sciences. The Chameleon team has over 25 years of experience in the … [Read more…]

MINNEAPOLIS–(BUSINESS WIRE)–DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on the Company’s Phase 2/3 ReMEDy2 trial studying the use of the Company’s product candidate, DM199, to treat acute … [Read more…]

LA JOLLA, Calif.–(BUSINESS WIRE)–DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today its membership in the Corporate Council of the Pediatric Dermatology Research Alliance (PeDRA). PeDRA is a nonprofit research network with the mission to create, inspire and sustain research to prevent, … [Read more…]

Live Conference Call and Webcast at 5:00 p.m. EDT SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will disclose its completion of the ATA188 Phase … [Read more…]